Schering's Intron-A
Executive Summary
The firm's alpha-2 interferon has received preliminary approval in the U.K. for treatment of hairy cell leukemia, pending approval of final product labeling. Intron-A is already on the market in Ireland for four cancer indications and venereal warts.